Pliant Therapeutics (PLRX) Stock: Buy, Sell, or Hold?
PLRX - Pliant Therapeutics, Inc. Common Stock
$1.17
0.04 (3.54%)
▲
5d:
+3.54%
30d:
+9.35%
90d:
+2.63%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When PLRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PLRX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PLRX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: PLRX is currently trading at $1.17, which is considered extended relative to its 30-day fair value range of $1.07 to $1.16.
Technical Outlook: Technically, PLRX is in a downtrend. The price is approaching resistance at $1.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Implied Volatility is high (99th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $2.00 (+70.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PLRX is in a downtrend. The price is approaching resistance at $1.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Implied Volatility is high (99th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $2.00 (+70.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.07 -
$1.16
Company Quality Score
46/100
(HOLD)
Options IV Signal
99th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
44.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Options expensive (IV 99th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 70.9% below Wall St target ($2.00)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.07 -
$1.16
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.56
(47.7%)
Support & Resistance Levels
Support Level
$1.09
Resistance Level
$1.19
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.91
Wall Street Target
$2.00
(+70.9%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: September 12, 2026 2:33 PM ET
Data refreshes hourly during market hours. Next update: 3:33 PM
Data refreshes hourly during market hours. Next update: 3:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
|
LRMR
Larimar Therapeutics Inc |
STRONG BUY
11 analysts |
$14 | 58 HOLD |
